AHCL

Anlon Healthcare Share Price

 

 

Start SIP in AHCL

Start SIP

Performance

  • Low
  • ₹141
  • High
  • ₹150
  • 52 Week Low
  • ₹91
  • 52 Week High
  • ₹173
  • Open Price₹145
  • Previous Close₹144
  • Volume62,662

Investment Returns

  • Over 1 Month + 2.53%
  • Over 3 Month + 40.47%
  • Over 6 Month + 56.79%
  • Over 1 Year + 56.79%

Smart Investing Starts Here Start SIP with Anlon Healthcare for Steady Growth!

Invest Now

Anlon Healthcare Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 758
  • P/B Ratio
  • Average True Range
  • 8.72
  • EPS
  • 3.86
  • Dividend Yield
  • 0
  • MACD Signal
  • 5.25
  • RSI
  • 44.25
  • MFI
  • 48.11

Anlon Healthcare Financials

Anlon Healthcare Technicals

EMA & SMA

Current Price
₹142.68
-1.81 (-1.25%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 2
  • 20 Day
  • ₹149.84
  • 50 Day
  • ₹140.32
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

144.54 Pivot Speed
  • R3 157.04
  • R2 153.49
  • R1 148.09
  • S1 139.14
  • S2 135.59
  • S3 130.19

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Anlon Healthcare, manufactures pharmaceutical bulk drugs and intermediates with advanced API facilities and strong R&D. Its products meet FDA, PMDA, KFDA, cGMP, and WHO-GMP standards, serving global healthcare needs with quality, compliance, and speed-to-market focus.

Anlon Healthcare Ltd has an operating revenue of Rs. 229.95 Cr. on a trailing 12-month basis. An annual revenue growth of 81% is outstanding, Pre-tax margin of 22% is great, ROE of 25% is exceptional. The company has a reasonable debt to equity of 48%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 5% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It has recently broken out of a base in its weekly chart and is trading around -2% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 95 which is a GREAT score indicating consistency in earnings, a RS Rating of 93 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 57 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Anlon Healthcare Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-11 Quarterly Results
2025-10-16 Others Inter-alia, to consider 1. The Expansion plan of the Companys business operation through existing facility expansion and/or acquisition strategy. 2. Other business matters.
2025-09-27 Others Inter-alia, to consider 1. Proposal for purchase of immovable property (Commercial Office) situated at Golden Crown, New 150 Feet Ring Road, Rajkot - 360005, Gujarat. 2. Other business matters.

Anlon Healthcare F&O

Anlon Healthcare Shareholding Pattern

52.68%
0.31%
0%
20.73%
26.28%

About Anlon Healthcare

  • NSE Symbol
  • AHCL
  • BSE Symbol
  • 544497
  • Chairman & Managing Director
  • Mr. Punitkumar R Rasadia
  • ISIN
  • INE0Y8W01017

Similar Stocks to Anlon Healthcare

Anlon Healthcare FAQs

Anlon Healthcare share price is ₹142 As on 10 December, 2025 | 20:11

The Market Cap of Anlon Healthcare is ₹758.4 Cr As on 10 December, 2025 | 20:11

The P/E ratio of Anlon Healthcare is As on 10 December, 2025 | 20:11

The PB ratio of Anlon Healthcare is 8.1 As on 10 December, 2025 | 20:11

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23